The Renal Cancer Lab, Division of Experimental Oncology, Urological Research Institute, develops many clinical and preclinical research lines in the field of kidney cancer. Areas of interest include 1) sporadic renal cell carcinoma (RCC) and 2) familiar RCC. The highest resonance of our work in the international scientific community has been reached with studies published in the following areas:

• Staging and prognosis of renal cell carcinoma
• Role of lymph node dissection and lymph node invasion in patients with kidney cancer
• Impact of minimally invasive surgery in the field of kidney cancer
• Optimization of the functional outcomes of patients with kidney cancer
• Multidisciplinary management of patient with renal cancer
• Definition of models predictive of therapeutic success (nomograms) for risk stratification of patients with kidney cancer
• Urine and blood RCC biomarkers
• Von Hippel Lindau syndrome

The Renal Cancer Lab is conducting two dedicated prospective translational trials focusing on heterogeneity in renal cancer in the context of sporadic kidney cancer and Von Hippel Lindau syndrome, both independently funded by international programs.

Click here to view our publications